Daniel M. G.
- Country
- Spain
- Department
- Hematology
Research Overview
- Evaluation of Brentuximab Vedotin, Doxorubicin Hydrochloride, Dacarbazine, and Nivolumab in Untreated Classical Hodgkin Lymphoma Patients
- Investigation of HDP-102 in Patients with Relapsed/Refractory B-cell Malignancies
- Phase 1 Evaluation of JNJ-89853413 in Relapsed/Refractory Acute Myeloid Leukemia and Higher-risk Myelodysplastic Neoplasms
Data & Insights
Has run more than one trial at 3 of 16 partner sites.
Specializations
Lymphoma Research
The investigator specializes in treating classical Hodgkin Lymphoma and diffuse large B-cell lymphoma (DLBCL), with particular emphasis on addressing relapsed and refractory cases.
- Classical Hodgkin Lymphoma Management
- Refractory DLBCL Treatment
- Novel Therapeutic Combinations
The research focus includes investigating targeted therapies and combination treatments for lymphoid malignancies.
Leukemia Studies
The investigator conducts research in acute myeloid leukemia (AML), specifically focusing on developing treatments for patients with relapsed or refractory disease states.
- Refractory AML Treatment
- Novel Therapeutic Approaches
- Treatment-Resistant Disease
Their work encompasses innovative therapeutic strategies for challenging hematologic conditions.
Myeloid Disorders
The investigator explores treatments for myelodysplastic neoplasms, with specific attention to higher-risk variants and refractory cases.
- Higher-Risk MDS Treatment
- Refractory Disease Management
- Progressive Disease Interventions
Research activities focus on developing effective interventions for challenging myeloid conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.